Temporal expression of c-fos mRNA following balloon injury in the rat common carotid artery.
OBJECTIVE
Restenosis is a common problem which limits the effectiveness of percutaneous transluminal coronary angioplasty (PTCA). The cellular mechanisms of restenosis appear to involve smooth muscle cell (SMC) migration to the neointima in response to mitogens and growth factors, resulting in proliferation and deposition of cells in the lumen of the vessel. An antibody directed against PDGF attenuates this response in the rat. Thus, signaling cascades induced by growth factors including PDGF may be important targets for therapeutic intervention.


METHODS
Since a number of growth factors activate c-fos via the p21-ras signaling pathway, we examined c-fos expression in a time course experiment involving restenotic lesions in rat carotid arteries. Sections of arteries collected at 1, 3, 7, 14 and 28 days following balloon injury were hybridized using a fluorescein-labeled RNA probe to c-fos. Immunohistochemistry was performed with antibodies to proliferating cell nuclear antigen (PCNA) and alpha-smc actin to characterize cellular constituents of the neointima, and detect any correlation between fos expression and PCNA localization.


RESULTS
Expression of c-fos was low at day 1. By day 3, the media and adventitia were positively stained. At days 7 and 14, most cells in the neointima were labeled. By day 28, c-fos was expressed mainly in scattered cells along the luminal surface. Control sections revealed little labeling and confirmed specific staining by the antisense strand, PCNA localization and c-fos expression were similar at days 1, 3, 7 and 28, but at day 14 c-fos was expressed throughout the lesion, with PCNA localized mainly along the luminal edge. The majority of the cells making up the neointima stained rather intensely for alpha-smc actin, identifying them as SMCs.


CONCLUSIONS
Results of these experiments indicate that, while c-fos expression correlates with lesion formation, it may be associated with a cellular process distinct from proliferation in this model.
Mills
C J
CJ
Cardiovascular Pharmacology, Pharmacia and Upjohn, Inc., Kalamazoo, MI 49007, USA.
Northrup
J L
JL
Hullinger
T G
TG
Simmons
C A
CA
Shebuski
R J
RJ
Jones
D A
DA
D000818:Animals; D020212:Carotid Artery Injuries; D017536:Carotid Artery, Common / Q000473:pathology / Q000502:physiology; D016893:Carotid Stenosis / Q000628:therapy; D002404:Catheterization / Q000009:adverse effects*; D015870:Gene Expression; D016762:Genes, fos; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000473:pathology; D018809:Proliferating Cell Nuclear Antigen / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012008:Recurrence; D013997:Time Factors; D017539:Tunica Intima / Q000473:pathology
D018809:Proliferating Cell Nuclear Antigen; D012333:RNA, Messenger